Compare Infosys Limited (INFY) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Revvity Inc — how do they compare? Infosys Limited trades at $10.73 (market cap $41.74B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: Infosys Limited is far larger — about 2.5× Revvity Inc's market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Revvity Inc for 12 Days on average.
| INFY | RVTY | |
|---|---|---|
Market Cap | $41.74B | $16.98B |
Volume | 31,354,285 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $20.22 | $157.36 |
52-Week Low | $10.49 | $82.26 |
Typical Hold Time | 27 Days | 12 Days |
Enterprise Value | $39.48B | $19.30B |
Dividend Yield | 4.89% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.70, up 1.42% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong profitability with a 16.37% net income margin and ROE of 32.12%. Recent news highlights strategic AI collaborations with Columbia University and ABN Amro. Earnings history shows mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering potential upside. Risks include competitive pressures in IT services and volatile cash flow trends, with net cash flow turning negative in 2026. Analyst sentiment is mixed, with 35% buy ratings but 55% hold, reflecting uncertainty amid steady fundamentals.
RVTY trades at $152.16, down 0.94% today, near its recent 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for three consecutive quarters. Recent positive developments include a Zacks upgrade to Buy (2026-10-02) and the launch of a new Type 1 diabetes screening kit in Europe (Business Wire, 2026-09-24).
The outlook is positive, supported by earnings momentum and strategic expansions, but the stock's premium valuation (P/E of 73.15) and margin pressures pose risks. Analyst consensus is bullish with a $132.13 price target, though the current price exceeds it, suggesting near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
